1. Home
  2. GECC vs XBIT Comparison

GECC vs XBIT Comparison

Compare GECC & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GECC

Great Elm Capital Corp.

HOLD

Current Price

$5.24

Market Cap

84.6M

Sector

Finance

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.26

Market Cap

69.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GECC
XBIT
Founded
2016
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.6M
69.8M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
GECC
XBIT
Price
$5.24
$2.26
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.75
N/A
AVG Volume (30 Days)
51.2K
42.6K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
22.06%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$0.92
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.63
$2.09
52 Week High
$11.45
$3.61

Technical Indicators

Market Signals
Indicator
GECC
XBIT
Relative Strength Index (RSI) 36.17 45.74
Support Level $5.14 $2.27
Resistance Level $5.37 $2.42
Average True Range (ATR) 0.17 0.05
MACD 0.00 0.00
Stochastic Oscillator 10.53 43.48

Price Performance

Historical Comparison
GECC
XBIT

About GECC Great Elm Capital Corp.

Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: